Empagliflozin/linagliptin FDC was effective & generally well tolerated in Japanese patients with T2DM, with consistent safety & efficacy outcomes across age grps; <65, ≥65 to <75, & ≥75 yrs.
No new safety concerns were identified during the study.
In three diabetic papillopathy cases, intravitreal bevacizumab with oral steroids achieved rapid disc edema resolution, OCT-confirmed RNFL thinning, marked gains in visual field and acuity, and no intraocular pressure rise or adverse events.